Scarica l'app Stockscreener
6.04
5.04%
0.29
Precedente Chiudi:
$5.75
Aprire:
$5.75
Volume 24 ore:
432.83K
Relative Volume:
2.14
Capitalizzazione di mercato:
$125.65M
Reddito:
-
Utile/perdita netta:
$-117.17M
Rapporto P/E:
-4.5414
EPS:
-1.33
Flusso di cassa netto:
$-91.71M
1 W Prestazione:
-11.95%
1M Prestazione:
-25.80%
6M Prestazione:
-23.54%
1 anno Prestazione:
-28.11%
Intervallo 1D:
$5.69
$6.15
Intervallo di 1 settimana:
$5.69
$7.7288
Portata 52W:
$5.69
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ADVM | 6.04 | 125.65M | 0 | -117.17M | -91.71M | -1.33 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Adverum Biotechnologies (NASDAQ:ADVM) Receives Buy Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum's Ixo-vec Shows 80%+ Treatment Reduction in Wet AMD Clinical Trials | ADVM Stock News - StockTitan
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Adverum to present gene therapy data for eye disease - Investing.com India
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - The Manila Times
Adverum to present gene therapy data for eye disease By Investing.com - Investing.com UK
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
FMR LLC Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is BML Capital Management LLC's 6th Largest Position - MarketBeat
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles By Investing.com - Investing.com Nigeria
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles - Investing.com India
FY2024 Earnings Forecast for ADVM Issued By Chardan Capital - MarketBeat
HC Wainwright Issues Pessimistic Forecast for ADVM Earnings - Defense World
Morgan Stanley's Strategic Reduction in Adverum Biotechnologies Inc Shares - GuruFocus.com
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Posts Earnings Results - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Thomas Chalberg - World Economic Forum
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
When (ADVM) Moves Investors should Listen - Stock Traders Daily
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies names new chief commercial officer - Investing.com
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan
Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat
Adverum Biotechnologies to Host Webcast to Review Clinical - GlobeNewswire
ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com
Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):